Ocular Drug Delivery: Advancements and Innovations
Open accessThe DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.
Abstract
Ocular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of “drug delivery” for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Presently, there are more than 40 active clinical trials or follow ups for ocular diseases using AAV vectors alone.154”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 9×
“Since the advent of the first FDA‐approved gene therapy, LuxturnaTM, for the treatment of type 2 Leber congenital amaurosis (LCA) [4], ophthalmic gene therapy research has blossomed.”
BackgroundMethodInfluentialDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“They are small (~26 nm diameter), icosahedral-structured capsid, non-enveloped, singlestranded DNA, non-pathogenic viruses [11].”
BackgroundNanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,226
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Anderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727 · cited 1×
“Recent advances have identified the complement cascade as playing a role in the development of drusen, which forms over the macula, leading to central-vision loss [18,19].”
BackgroundMahapatro, A., & Singh, D. K. (2011) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-9-55 · Cited by 685
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 605
Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 475
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Advances and limitations of drug delivery systems formulated as eye drops
Jumelle, C., Gholizadeh, S., Annabi, N., & Dana, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.057 · Cited by 408
Current management of glaucoma
Lusthaus, J., & Goldberg, I. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50020 · Cited by 354 · cited 1×
“Despite multiple mechanisms that are involved in glaucoma development and progression, lowering the IOP is currently the main treatment regimen, including daily eye drops or surgery [29].”
BackgroundRai, R., Alwani, S., & Badea, I. (2019) · Polymers · doi:10.3390/polym11040745 · Cited by 350
Recent advances in ocular drug delivery
Achouri, D., Alhanout, K., Piccerelle, P., & Andrieu, V. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.736515 · Cited by 335
Ocular novel drug delivery: impacts of membranes and barriers
Barar, J., Javadzadeh, A. R., & Omidi, Y. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.5.567 · Cited by 308 · cited 1×
“The anterior chamber comprises the cornea, aqueous humor, and lens [1].”
Background2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Complications of intravitreal injections
Sampat, K. M., & Garg, S. J. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328338679a · Cited by 287
Inorganic nanoparticles in clinical trials and translations
Huang, H., Feng, W., Chen, Y., & Shi, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100972 · Cited by 283
Bolhassani, A., Javanzad, S., Saleh, T., Hashemi, M., Aghasadeghi, M. R., & Sadat, S. M. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26796 · Cited by 278
Capsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
Solid lipid nanoparticles for ocular drug delivery
Seyfoddin, A., Shaw, J., & Al-Kassas, R. (2010) · Drug Delivery · doi:10.3109/10717544.2010.483257 · Cited by 247
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238 · cited 1×
“Anti-VEGF (vascular endothelial growth factor) therapy blocks the activity of VEGF and has demonstrated significant benefits to neovascular AMD patients [20,21].”
BackgroundA review on recent drug delivery systems for posterior segment of eye
Nayak, K., & Misra, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.138 · Cited by 225
Lotery, A., Sivaprasad, S., O'Connell, A., Harris, R. A., Culliford, L., Ellis, L., Cree, A., Madhusudhan, S., Behar-Cohen, F., Chakravarthy, U., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32981-2 · Cited by 225
Three Decades of Corneal Transplantation: Indications and Patient Characteristics
Maeno, A., Naor, J., Lee, H. M., Hunter, W. S., & Rootman, D. S. (2000) · Cornea · doi:10.1097/00003226-200001000-00002 · Cited by 214
Omri, S., Behar-Cohen, F., de Kozak, Y., Sennlaub, F., Mafra Verissimo, L., Jonet, L., Savoldelli, M., Omri, B., & Crisanti, P. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.04.018 · Cited by 213
A comprehensive review on contact lens for ophthalmic drug delivery
Xu, J., Xue, Y., Hu, G., Lin, T., Gou, J., Yin, T., He, H., Zhang, Y., & Tang, X. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.020 · Cited by 213
Strategies to prolong the residence time of drug delivery systems on ocular surface
Grassiri, B., Zambito, Y., & Bernkop-Schnürch, A. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102342 · Cited by 199
Advances in ophthalmic drug delivery
Morrison, P. W., & Khutoryanskiy, V. V. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.75 · Cited by 196
Multicenter study of compliance and drop administration in glaucoma
Kholdebarin, R., Campbell, R. J., Jin, Y.-P., & Buys, Y. M. (2008) · Canadian Journal of Ophthalmology · doi:10.3129/i08-076 · Cited by 194
Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery
Khiev, D., Mohamed, Z. A., Vichare, R., Paulson, R., Bhatia, S., Mohapatra, S., Lobo, G. P., Valapala, M., Kerur, N., Passaglia, C. L., et al. (2021) · Nanomaterials · doi:10.3390/nano11010173 · Cited by 180
Li, J. Q., Welchowski, T., Schmid, M., Letow, J., Wolpers, C., Pascual-Camps, I., Holz, F. G., & Finger, R. P. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-019-00560-z · Cited by 179 · cited 1×
“Diabetic retinopathy (DR) is one of the most common complications of diabetes mellitus (DM) and is one of the leading causes of preventable vision loss in the developed world [24].”
BackgroundMathews, P. M., Lindsley, K. B., Aldave, A. J., & Akpek, E. K. (2018) · Cornea · doi:10.1097/ico.0000000000001666 · Cited by 174
The blood-retinal barrier: structure and functional significance
Runkle, E. A., & Antonetti, D. A. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-60761-938-3_5 · Cited by 171
Age-related macular degeneration and the complement system
Khandhadia, S., Cipriani, V., Yates, J. R. W., & Lotery, A. J. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.07.019 · Cited by 167 · cited 1×
“Recent advances have identified the complement cascade as playing a role in the development of drusen, which forms over the macula, leading to central-vision loss [18,19].”
BackgroundA novel cationic niosome formulation for gene delivery to the retina
Puras, G., Mashal, M., Zárate, J., Agirre, M., Ojeda, E., Grijalvo, S., Eritja, R., Diaz-Tahoces, A., Martínez Navarrete, G., Avilés-Trigueros, M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.004 · Cited by 164
Controlled ocular drug delivery with nanomicelles
Vaishya, R. D., Khurana, V., Patel, S., & Mitra, A. K. (2014) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1272 · Cited by 162
Considerations for Polymers Used in Ocular Drug Delivery
Allyn, M. M., Luo, R. H., Hellwarth, E. B., & Swindle-Reilly, K. E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.787644 · Cited by 159
Carter, B. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.011 · Cited by 157 · cited 2×
“Adeno-associated viruses (AAVs) were originally discovered in the mid-1960s as satellite viruses associated with adenoviruses, hence the name ‘adeno-associated’ [10].”
BackgroundHigh-risk Corneal Transplantation: Recent Developments and Future Possibilities
Armitage, W. J., Goodchild, C., Griffin, M. D., Gunn, D. J., Hjortdal, J., Lohan, P., Murphy, C. C., Pleyer, U., Ritter, T., Tole, D. M., et al. (2019) · Transplantation · doi:10.1097/tp.0000000000002938 · Cited by 157
Multicenter study of compliance and drop administration in glaucoma.
Kholdebarin, R., Campbell, R. J., Jin, Y.-P., et al. (2008) · PubMed · doi:10.1139/i08-076 · Cited by 153 · cited 8×
“However, in 2019, a Phase III trial of OTX-TP (travoprost punctal plug insert) for the treatment of glaucoma failed to show statistically significant superiority of mean reduction in IOP, compared with the placebo [104].”
BackgroundInfluentialDNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64833 · Cited by 150
Understanding Trabecular Meshwork Physiology: A Key to the Control of Intraocular Pressure?
Llobet, A., Gasull, X., & Gual, A. (2003) · Physiology · doi:10.1152/nips.01443.2003 · Cited by 143 · cited 1×
“IOP is maintained physiologically by the trabecular meshwork (TM) in the anterior chamber of the eye [31].”
BackgroundExtraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Kompella, U. B., Hartman, R. R., & Patil, M. A. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100901 · Cited by 133
Mantravadi, A. V., & Vadhar, N. R. (2015) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2015.05.008 · Cited by 132
Lewis, R. A., Christie, W. C., Day, D. G., Craven, E. R., Walters, T., Bejanian, M., Lee, S. S., Goodkin, M. L., Zhang, J., Whitcup, S. M., et al. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.11.020 · Cited by 127
Age-Related Macular Degeneration
Mehta, S. (2015) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2015.05.009 · Cited by 126 · cited 1×
“Although advances in cancer biology have given the field potent neovascularization inhibitors, the underlying pathology of the dry form is still poorly understood [17].”
BackgroundCai, X., Conley, S. M., Nash, Z. A., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · The FASEB Journal · doi:10.1096/fj.09-139147 · Cited by 123
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119 · cited 2×
“Although the pathologies of these disorders are more complex than monogenetic inherited diseases, the identification of specific thera‐ peutic targets and the lack of need for repeat dosing has generated much interest for the potential of AAV‐mediated gene therapy to treat diseases, such as age‐related macular degener…”
BackgroundGene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease
Prado, D. A., Acosta-Acero, M., & Maldonado, R. S. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000660 · Cited by 114 · cited 2×
“Despite of the initial exploration for inherited disorders in the field, applications of gene therapy are expanding beyond rare inherited diseases to acquired disorders with higher prevalence, including age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, and corneal diseases [5].”
BackgroundUse of Retinal Procedures in Medicare Beneficiaries From 1997 to 2007
Ramulu, P. Y. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.224 · Cited by 113
Mohan, R. R., Tovey, J. C. K., Sharma, A., Schultz, G. S., Cowden, J. W., & Tandon, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026432 · Cited by 112
Vitiello, L., Chonn, A., Wasserman, J. D., Duff, C., & Worton, R. G. (1996) · PubMed · Cited by 104
Nanoparticles for retinal gene therapy
Conley, S. M., & Naash, M. I. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.004 · Cited by 101
Molecular Design for Enhancement of Ocular Penetration
Shirasaki, Y. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21200 · Cited by 101
Mohan, R. R., Tandon, A., Sharma, A., Cowden, J. W., & Tovey, J. C. K. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7357 · Cited by 100
Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration
Campa, C., & P. Harding, S. (2011) · Current Drug Targets · doi:10.2174/138945011794182674 · Cited by 100 · cited 1×
“Anti-VEGF (vascular endothelial growth factor) therapy blocks the activity of VEGF and has demonstrated significant benefits to neovascular AMD patients [20,21].”
BackgroundAnterior Eye Segment Drug Delivery Systems: Current Treatments and Future Challenges
Molokhia, S. A., Thomas, S., Garff, K. J., Mandell, K. J., & Wirostko, B. M. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0241 · Cited by 100
Buie, L. K., Rasmussen, C. A., Porterfield, E. C., Ramgolam, V. S., Choi, V. W., Markovic‐Plese, S., Samulski, R. J., Kaufman, P. L., & Borrás, T. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3847 · Cited by 100 · cited 1×
“GFP in non-human primates (NHPs) was shown to result in fluorescence in the TM for 2 years post-injection [33].”
BackgroundLipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93
Targeted AAV5-Smad7 gene therapy inhibits corneal scarring in vivo
Gupta, S., Rodier, J. T., Sharma, A., Giuliano, E. A., Sinha, P. R., Hesemann, N. P., Ghosh, A., & Mohan, R. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172928 · Cited by 90
Lin, S., Ge, C., Wang, D., Xie, Q., Wu, B., Wang, J., Nan, K., Zheng, Q., & Chen, W. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b13851 · Cited by 88
Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases
Kansara, V., Muya, L., Wan, C.-R., & Ciulla, T. A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0126 · Cited by 84 · cited 1×
“SCS injections are a less invasive procedure than intravitreal injections that could potentially offer a higher transduction efficiency of the RPE and photoreceptor cell layer [23].”
BackgroundPsychological impact of anti-VEGF treatments for wet macular degeneration—a review
Senra, H., Ali, Z. C., Balaskas, K., & Aslam, T. M. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3384-0 · Cited by 84 · cited 1×
“However, anti-VEGF therapy is hampered by the short half-life of the protein drug and, therefore, demands frequent intravitreal injections, which places a high burden on both the patient and provider [22].”
BackgroundGene mapping of ocular diseases
Musarella, M. A. (1992) · Survey of Ophthalmology · doi:10.1016/0039-6257(92)90096-c · Cited by 82 · cited 1×
“There are more than 350 hereditary ocular diseases, including retinitis pigmentosa, choroideremia, Stargardt disease, Leber’s congenital amaurosis (LCA), involving a wide diversity of genetic loci [6,7].”
BackgroundDohlman, T. H., Omoto, M., Hua, J., STEVENSON, W. C., Lee, S. M., Chauhan, S. K., & Dana, R. (2015) · Transplantation · doi:10.1097/tp.0000000000000512 · Cited by 81
First-in-Human robot-assisted subretinal drug delivery under local anesthesia
Cehajic-Kapetanovic, J., Xue, K., Edwards, T. L., Meenink, T. C., Beelen, M. J., Naus, G. J., de Smet, M. D., & MacLaren, R. E. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.11.011 · Cited by 78
Emerging potential of niosomes in ocular delivery
Verma, A., Tiwari, A., Saraf, S., Panda, P. K., Jain, A., & Jain, S. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1822322 · Cited by 78
Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
dos Santos, G. A., Ferreira‐Nunes, R., Dalmolin, L. F., Ré, A. C. D. S., dos Anjos, J. L. V., Mendanha, S. A., Aires, C. P., Lopez, R. F. V., Filho, M. C., Gelfuso, G. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76381-y · Cited by 76
Cationic nanoemulsions as nucleic acids delivery systems
Teixeira, H. F., Bruxel, F., Fraga, M., Schuh, R. S., Zorzi, G. K., Matte, Ú. D. S., & Fattal, E. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.10.030 · Cited by 75
Nanoemulsions as Ophthalmic Drug Delivery Systems
Dhahir, R. K., Al-Nima, A. M., & Al-bazzaz, F. Y. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2020.59319 · Cited by 75
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye
Cheng, K., Hsieh, C., Nepali, K., & Liou, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01033 · Cited by 73 · cited 1×
“There are more than 350 hereditary ocular diseases, including retinitis pigmentosa, choroideremia, Stargardt disease, Leber’s congenital amaurosis (LCA), involving a wide diversity of genetic loci [6,7].”
BackgroundToropainen, E., Fraser‐Miller, S. J., Novakovic, D., del Amo, E. M., Vellonen, K., Ruponen, M., Viitala, T., Korhonen, O., Auriola, S. O. K., Hellinen, L., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040452 · Cited by 72
Updates on Gene Therapy for Diabetic Retinopathy
Wang, J.-H., Roberts, G. E., & Liu, G. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01308-w · Cited by 69 · cited 2×
“Although the pathologies of these disorders are more complex than monogenetic inherited diseases, the identification of specific thera‐ peutic targets and the lack of need for repeat dosing has generated much interest for the potential of AAV‐mediated gene therapy to treat diseases, such as age‐related macular degener…”
BackgroundProtection of retinal ganglion cells in glaucoma: Current status and future
Shen, J., Wang, Y., & Yao, K. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108506 · Cited by 68 · cited 8×
“However, in 2019, a Phase III trial of OTX-TP (travoprost punctal plug insert) for the treatment of glaucoma failed to show statistically significant superiority of mean reduction in IOP, compared with the placebo [104].”
BackgroundInfluentialThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
Oral eplerenone for the management of chronic central serous chorioretinopathy.
Singh, R. P., Sears, J. E., Bedi, R., SCHACHAT, A. P., Ehlers, J. P., & Kaiser, P. K. (2015) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2015.02.17 · Cited by 67
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
Lotan, I., Charlson, R. W., Ryerson, L. Z., Levy, M., & Kister, I. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101920 · Cited by 65
Clinical experience with eplerenone to treat chronic central serous chorioretinopathy
Cakir, B., Fischer, F., Ehlken, C., Bühler, A., Stahl, A., Schlunck, G., Böhringer, D., Agostini, H. T., & Lange, C. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3373-3 · Cited by 63
Philpott, N. J., Giraud, C., Dupuis, C., Gomos, J. B., Hamilton, H., Berns, K. I., & Falck-Pedersen, E. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5411-5421.2002 · Cited by 62 · cited 1×
“9 kb for therapeutic applications (Figure 2) [12].”
BackgroundBill, A. (1986) · PubMed · Cited by 60
Sustained subconjunctival drug delivery systems: current trends and future perspectives
Rafiei, F., Tabesh, H., & Farzad, F. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01391-8 · Cited by 58
Silva, M., Peng, T., Zhao, X., Li, S., Farhan, M., & Zheng, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.007 · Cited by 58
Ramlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B., Steel, J. C., & Layton, C. J. (2019) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 57
Depot formulations to sustain periocular drug delivery to the posterior eye segment
Agban, Y., Thakur, S. S., Mugisho, O. O., & Rupenthal, I. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.023 · Cited by 57
Liu, C., Lee, G.-W., Wu, W., & Wang, C. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110726 · Cited by 57
Cyclodextrin–Amphiphilic Copolymer Supramolecular Assemblies for the Ocular Delivery of Natamycin
Lorenzo-Veiga, B., Sigurðsson, H. H., Loftsson, Þ., & Alvarez‐Lorenzo, C. (2019) · Nanomaterials · doi:10.3390/nano9050745 · Cited by 56
The suprachoroidal pathway: a new drug delivery route to the back of the eye
Do, U., Young, S. A., Thrimawithana, T. R., Abdelkader, H., Alani, A. W. G., Pierscionek, B. K., & Alany, R. G. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.010 · Cited by 55
Watson, Z. L., Washington, S. D., Phelan, D. M., Lewin, A. S., Tuli, S. S., Schultz, G. S., Neumann, D. M., & Bloom, D. C. (2018) · Journal of Virology · doi:10.1128/jvi.00812-18 · Cited by 55
Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
Bastola, P., Song, L., Gilger, B. C., & Hirsch, M. L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080767 · Cited by 52
Loftsson, Þ., & Stefánsson, E. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14861 · Cited by 52
Mechanisms of AAV transduction in glaucoma‐associated human trabecular meshwork cells
Borrás, T., Xue, W., Choi, V. W., Bartlett, J. S., Li, G., Samulski, R. J., & Chisolm, S. S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.886 · Cited by 51
Yoon, K. C., Ahn, K. Y., Lee, J. H., Chun, B. J., Park, S. W., Seo, M. S., Park, Y.-G., & Kim, K. K. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302442 · Cited by 51
The probability of having glaucoma at different IOP levels
Davanger, M., Ringvold, A., & Blika, S. (1991) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.1991.tb04840.x · Cited by 51 · cited 1×
“Elevated intraocular pressure (IOP) is a major risk factor associated with optic neuropathy [27].”
Background[Possibility of the application of ophthalmic drugs with the use of gel contact lenses].
Sedlácek, J. (1965) · PubMed · Cited by 51
Sun, D., Sahu, B., Gao, S., Schur, R. M., Vaidya, A. M., Maeda, A., Palczewski, K., & Lu, Z.-R. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.02.005 · Cited by 47
Qin, Y., Tian, Y., Liu, Y., Li, D., Zhang, H., Yang, Y., Qi, J., Wang, H., & Gan, L. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12940 · Cited by 42
Chu, H.-S., Hu, F., Yang, C., Yeh, P., Chen, Y.-M., Hou, Y., & Chen, W. (2010) · Cornea · doi:10.1097/ico.0b013e3181e458c5 · Cited by 40
Cho, Y. K., Uehara, H., Young, J. R., Tyagi, P., Kompella, U. B., Zhang, X., Luo, L., Singh, N., Archer, B. J., & Ambati, B. K. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8393 · Cited by 39
Intrastromal voriconazole: An adjuvant approach for recalcitrant mycotic keratitis
Konar, P., Joshi, S., Mandhare, S. J., Thakur, R., Deshpande, M., & Dayal, A. (2019) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_378_19 · Cited by 39
Saluja, G., Sharma, N., Agarwal, R., Sharma, H. P., Singhal, D., Maharana, P. K., Sinha, R., Agarwal, T., Velpandian, T., Titiyal, J. S., et al. (2021) · Clinical ophthalmology · doi:10.2147/opth.s301878 · Cited by 39
Hirsch, M. L., Conatser, L., Smith, S. M., Salmon, J. H., Wu, J. C., Buglak, N., Davis, R., & Gilger, B. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-18002-9 · Cited by 38
Vicente-Pascual, M., Gómez-Aguado, I., Rodríguez-Castejón, J., Rodríguez‐Gascón, A., Muntoni, E., Battaglia, L., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060584 · Cited by 36
Miyadera, K., Conatser, L., Llanga, T., Carlin, K., O’Donnell, P., Bagel, J. H., Song, L., Kurtzberg, J., Samulski, R. J., Gilger, B. C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.004 · Cited by 35
Looking into the future: Gene and cell therapies for glaucoma
Komáromy, A. M., Koehl, K. L., & Park, S. A. (2021) · Veterinary Ophthalmology · doi:10.1111/vop.12858 · Cited by 33 · cited 2×
“Although the pathologies of these disorders are more complex than monogenetic inherited diseases, the identification of specific thera‐ peutic targets and the lack of need for repeat dosing has generated much interest for the potential of AAV‐mediated gene therapy to treat diseases, such as age‐related macular degener…”
BackgroundOral medications for central serous chorioretinopathy: a literature review
Fusi-Rubiano, W., Saedon, H., Patel, V., & Yang, Y. C. (2019) · Eye · doi:10.1038/s41433-019-0568-y · Cited by 32
Pathophysiology of Diabetic Retinopathy
Stewart, M. W. (2010) · Springer eBooks · doi:10.1007/978-0-387-85900-2_1 · Cited by 30
Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema
Maleki, A., Aghaei, H., & Lee, S. (2018) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2018.03.005 · Cited by 30
Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab
Silkiss, R. Z., Paap, M. K., Roelofs, K. A., Agi, J., & Weis, E. (2020) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2020.07.020 · Cited by 30
New Frontiers of Corneal Gene Therapy
Iorio, E. D., Barbaro, V., Alvisi, G., Trevisan, M., Ferrari, S., Masi, G., Nespeca, P., Ghassabian, H., Ponzin, D., & Palù, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.026 · Cited by 28
Incidence and Characteristics of Cystoid Macular Edema after Cataract Surgery
Daïen, V., Papinaud, L., Domerg, C., Lacombe, S., Daurès, J. P., & Villain, M. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.009 · Cited by 28
Rodríguez-Estévez, L., Asokan, P., & Borrás, T. (2019) · Gene Therapy · doi:10.1038/s41434-019-0105-4 · Cited by 25 · cited 1×
“examined the transduction efficiency and cellular entry of seven serotypes of AAV in both the ss and ds forms and found that the ds form consistently had a 10x higher transduction efficiency [34].”
BackgroundKansara, V. S., Cooper, M. J., Sesenoglu‐Laird, O., Muya, L. W., Moen, R. C., & Ciulla, T. A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.13.21 · Cited by 25
Eplerenone for treatment of chronic central serous chorioretinopathy
Fraenkel, D., Suffo, S., Langenbucher, A., Seitz, B., & Abdin, A. D. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120952648 · Cited by 25
Su, W., Sun, S., Tian, B., Tai, P. W. L., Luo, Y., Ko, J., Zhan, W., Xiao, K., Zheng, Q., Li, X., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.007 · Cited by 25
Self-citationOverexpression of BMP4 protects retinal ganglion cells in a mouse model of experimental glaucoma
Liu, D., Deng, Q., Lei, X., Lü, W., Zhao, Q., & Shen, Y. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108728 · Cited by 24
Zhang, N., Luo, X., Zhang, S., Liu, R., Liang, L., Su, W., & Liang, D. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-05017-8 · Cited by 24
Self-citationAbbasi, M., Gupta, V., Chitranshi, N., Gupta, V. B., Ranjbaran, R., Rajput, R., Pushpitha, K., Devaraj, K. B., You, Y., Salekdeh, G. H., et al. (2021) · Theranostics · doi:10.7150/thno.55472 · Cited by 23
Evolving Guidelines for Intracameral Injection
Liebmann, J. M., Barton, K., Weinreb, R. N., Eichenbaum, D. A., Gupta, P. K., McCabe, C. M., Wolfe, J. D., Ahmed, I. I. K., Sheybani, A., & Craven, E. R. (2020) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001451 · Cited by 23
de Oliveira, F. A., Albuquerque, L. J. C., Delecourt, G., Bennevault, V., Guégan, P., & Giacomelli, F. C. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210705130238 · Cited by 16
Vooturi, S. K., Bourne, D. W. A., Panda, J. J., Choi, S. H., Kim, H., Yandrapu, S. K., & Kompella, U. B. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0150 · Cited by 15
Song, L., Bower, J. J., Llanga, T., Salmon, J. H., Hirsch, M. L., & Gilger, B. C. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.014 · Cited by 14
Updates on drug bioavailability and delivery to posterior segment of eye
Gupta, H. (2013) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.116792 · Cited by 9
Eplerenone Treatment in Chronic Central Serous Chorioretinopathy
Iqbal, F., Iqbal, K., Inayat, B., Arjumand, S., Ghafoor, Z., Sattar, W., & Abbas, K. (2021) · Cureus · doi:10.7759/cureus.18415 · Cited by 8
Recent advance technique for ocular drug delivery by Gupta et al.: Nanoparticle laden in situ gel
Kumar, M., & Gupta, P. (2013) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.116794 · Cited by 7
Gilger, B. C., Salmon, J. H., Roberts, D. M., Song, L., Bower, J. J., & Hirsch, M. L. (2021) · Investigative Ophthalmology & Visual Science · Cited by 2
Research works printed but not linked: 9
- Komaromy, 2021, Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP), Investig. Ophthalmol. Vis. Sci., 62, 2783
- Visuvanathan, S. (2019). The Effects of AAV-Mediated XIAP Gene Therapy in a Mouse Model of Glaucoma. [Master’s Thesis, Université d’Ottawa/University of Ottawa].
- Bilsbury, 2022, AAV-mediated anti-VEGF therapeutics increase corneal allograft survival-rate in a model of high-risk corneal transplantation, Investig. Ophthalmol. Vis. Sci., 63, 72-A0045
- Garrigue, 2011, A Comparative Study of Latanoprost-Cationic Emulsion (Catioprost) and Latanoprost Aqueous Solution (Xalatan) in Preclinical Efficacy and Safety Models, Investig. Ophthalmol. Vis. Sci., 52, 238
- Biswas, 2017, Niosomes in ocular drug delivery, Eur. J. Pharm. Med. Res, 4, 813
- Avti, P., Patel, S., and Sitharaman, B. (2016). Nanobiomaterials Handbook, CRC Press.
- Van Ooteghem, M.M. (2019). Biopharmaceutics of Ocular Drug Delivery, CRC Press.
- Varma, 2018, Sustained release drug delivery: Closer than you think, Glaucoma Today, 3, 58
- Sedlavek, 1965, Possibilities of application of ophthalmic drugs with the aid of gel contact lens, Cesk. Oftalmol., 21, 509
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Mucoadhesive-to-Mucopenetrating Nanoparticles for Mucosal Drug Delivery: A Mini Review
Zheng, B., Liu, D., Qin, X., Zhang, D., & Zhang, P. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505427 · Cited by 71
“As a result, insufficient release of the mucus-penetrating ligands eventually leads to the retention of nanoparticles in the mucus layer and their removal.”
How can machine learning and multiscale modeling benefit ocular drug development?
Wang, N., Zhang, Y., Wang, W., Ye, Z., Chen, H., Hu, G., & Ouyang, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114772 · Cited by 58
Kannan, R. M., Pitha, I., & Parikh, K. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115005 · Cited by 53
Chandel, A., & Kandav, G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105785 · Cited by 49
Metadata
- Authors
- Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Gao, Guangping
- Lin, Haijiang
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-09-13
- Volume
- 14
- Issue
- 9
- Pages
- 1931
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9506479
- OpenAlex
- W4296005586
- Cited by
- 50
- References
- 134
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 14 · 2023: 15
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- BrightFocus Foundation (M2019074)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- ocular drug delivery, ocular gene therapy, adeno-associated virus vectors, vector selection, gene therapy vectors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.